EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing

Bingrui Li iD, Xiaobo Zhou, Raghu Kalluri iD

Advanced Science · 2026

DOI: 10.1002/advs.202514502 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Bingrui Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. Hauptthemen laut MEDLINE: Sequence Analysis, RNA, Single-Cell Analysis, Computational Biology, Neoplasms. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NLM NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single‐cell RNA sequencing (scRNA‐seq) is a powerful technique for understanding cellular diversity, but processing large patient cohorts to identify phenotype‐associated cell populations remains challenging. Here, scPER ( E stimating cell P roportions using s ingle‐ c ell RNA‐seq R eference), a rigorous approach combining adversarial autoencoder and extreme gradient boosting to estimate tumor microenvironment cell compositions and identify phenotype‐associated subclusters for bulk RNA‐seq samples. Integrating scRNA‐seq datasets from diverse studies, scPER constructed comprehensive reference panels and disentangled confounders from true signals. scPER achieved superior accuracy in cellular proportion estimation compared to CIBERSORTx, BayesPrism, Scaden, MuSiC, SCDC, DeSide and ReCIDE. It showed high accuracy in predicting metastatic melanoma immunotherapy response and identified a critical T cell subcluster expressing FCRL3 and SLAMF7 . In metastatic urothelial cancer, scPER predicted TGFβ‐mediated inhibition of CD4 naïve T cells to diminish PD‐L1 checkpoint blockade efficacy. scPER enables robust integration of scRNA‐seq datasets to estimate cellular proportions across tumors and identify clinically relevant cell populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sequence Analysis, RNASingle-Cell AnalysisComputational BiologyNeoplasmsHumansPhenotypeTumor MicroenvironmentMelanomaRNA-Seq

Stichwörter der Autor:innen

cancer biologydeconvolutionmachine learningtumor microenvironment

Autor:innen und Institutionen

  • Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
  • Center for Computational Systems Medicine, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
  • McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA.
  • Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, USA.
  • Department of Bioengineering, Rice University, Houston, TX, 77005, USA.
  • Department of Electrical and Computer Engineering, Rice University, Houston, TX, 77005, USA.

ORCID-Profile: Bingrui Li, Raghu Kalluri

Förderung

  • NLM NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • CPRIT
  • National Science Foundation
  • Sid W. Richardson Foundation
  • MD Anderson Cancer Center
  • NIAAA NIH HHS

Zitieren

APA

Li, B., Zhou, X., & Kalluri, R. (2026). scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing. Advanced Science. https://doi.org/10.1002/advs.202514502

Vancouver

Li B, Zhou X, Kalluri R. scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing. Advanced Science. 2026. doi:10.1002/advs.202514502

BibTeX
@article{Li2026,
  author = {Li, Bingrui and Zhou, Xiaobo and Kalluri, Raghu},
  title = {scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202514502}
}
Kostenlos starten →